Literature DB >> 7873657

Analysis of sequences required for the cytotoxic action of a chimeric toxin composed of Pseudomonas exotoxin and transforming growth factor alpha.

A Kihara1, I Pastan.   

Abstract

Chimeric toxins composed of transforming growth factor alpha fused to mutant forms of Pseudomonas exotoxin bind to the EGF receptor and kill cells bearing these receptors. In early experiments, the binding domain of Pseudomonas exotoxin was deleted and replaced with TGF alpha to make TGF alpha-PE40. This chimeric toxin required proteolytic processing within the target cell to be converted to its active form (Siegall et al. (1989) FASEB J. 3, 2647-2652). Subsequently, recombinant toxins that do not require proteolytic processing were constructed by inserting TGF alpha near the carboxyl terminus of domain III and deleting toxin residues up to the processing site at position 280. In addition, the carboxyl terminus of this toxin was converted from REDLK to KDEL to increase its activity. Recombinant toxins of this type, termed PE37/TGF alpha/KDEL, are about 100-fold more potent than TGF alpha-PE40. To determine if other sequences can be removed from such chimeric toxins to make a smaller molecule that can penetrate tissues better, we have carried out a deletion analysis of sequences present within domains II and Ib. We find that all of domain Ib and a portion of domain II can be deleted without significant loss of cytotoxic activity, but larger deletions extending further into domain II lose cytotoxic activity. We also find that inserting a small linking peptide (Gly)4Ser between residual sequences in domain II and domain III, in molecules with diminished cytotoxic activity, enhances cytotoxicity suggesting that one role of domain Ib is to prevent undesirable interactions between domains II and III.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7873657     DOI: 10.1021/bc00030a008

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   6.069


  5 in total

1.  A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

Authors:  John E Weldon; Laiman Xiang; Oleg Chertov; Inger Margulies; Robert J Kreitman; David J FitzGerald; Ira Pastan
Journal:  Blood       Date:  2008-11-06       Impact factor: 25.476

Review 2.  A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.

Authors:  John E Weldon; Ira Pastan
Journal:  FEBS J       Date:  2011-06-02       Impact factor: 5.622

3.  Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation.

Authors:  M Li; F Dyda; I Benhar; I Pastan; D R Davies
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 12.779

4.  Improved antitumor activity of a recombinant anti-Lewis(y) immunotoxin not requiring proteolytic activation.

Authors:  C T Kuan; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-06       Impact factor: 12.779

5.  EGFR-targeted Chimeras of Pseudomonas ToxA released into the extracellular milieu by attenuated Salmonella selectively kill tumor cells.

Authors:  David Quintero; Jamie Carrafa; Lena Vincent; David Bermudes
Journal:  Biotechnol Bioeng       Date:  2016-07-08       Impact factor: 4.395

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.